ResMed's Trading Volume Surges 91.57% to $260 Million, Ranked 388th in Market

On May 27, 2025, ResMed's trading volume reached $260 million, marking a 91.57% increase from the previous day, placing it 388th in the day's stock market rankings. ResMed's stock price rose by 1.39%.

On May 22, 2025, Brett Sandercock, the Chief Financial Officer of ResMed, sold 3,644 shares worth $891,286. This transaction was reported in a Form 4 filing with the SEC. Following the sale, Sandercock's direct ownership in the company decreased by 4%, leaving him with 86,283 units.

Oppenheimer & Co. Inc. served as the exclusive financial advisor to VirtuOx, a software-enabled independent diagnostic testing facility, during its sale to ResMed. VirtuOx provides technology solutions for in-home and remote testing services for various health conditions, including sleep, respiratory, and cardiac issues. This acquisition aligns with ResMed's mission to enhance care delivery by making it more accessible, coordinated, and patient-friendly. VirtuOx's at-home diagnostic services will enable ResMed to support patients earlier in their healthcare journey and facilitate more connected care delivery for healthcare providers and homecare companies. The virtual testing platform offered by VirtuOx aims to reduce diagnostic barriers, providing fast, flexible, and affordable options for patients, particularly those with underdiagnosed conditions like sleep-disordered breathing.